Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Increased by Oliver Luxxe Assets LLC

Oliver Luxxe Assets LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,461 shares of the medical research company’s stock after buying an additional 555 shares during the period. Oliver Luxxe Assets LLC’s holdings in Thermo Fisher Scientific were worth $4,922,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of TMO. Legacy Investment Solutions LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $26,000. Peterson Financial Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $27,000. HWG Holdings LP purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $50,000. RPg Family Wealth Advisory LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $50,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in shares of Thermo Fisher Scientific in the third quarter worth $65,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TMO has been the topic of a number of research reports. Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Sanford C. Bernstein reduced their price target on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a report on Thursday, October 24th. Barclays dropped their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Finally, Bernstein Bank upped their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $650.05.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,150 shares of company stock worth $25,954,465 in the last quarter. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $4.39 during trading on Monday, reaching $536.41. 1,496,521 shares of the company traded hands, compared to its average volume of 1,580,253. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a market cap of $205.18 billion, a price-to-earnings ratio of 33.63, a P/E/G ratio of 3.54 and a beta of 0.76. The stock’s 50 day moving average price is $530.72 and its two-hundred day moving average price is $568.67. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same period in the prior year, the business posted $5.69 earnings per share. The business’s revenue was up .2% compared to the same quarter last year. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s payout ratio is presently 9.78%.

Thermo Fisher Scientific announced that its board has approved a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.